Arrowhead Research Corp. Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Aug 10 Calls Today's Calls

Call Details Arrowhead Research Corp. Earnings Conference Call (Q3 2009) Mon, Aug 10, 2009, 4:30 pm Eastern Listen to the archived event audio About Arrowhead Research Corp. (NasdaqCM:ARWR) Arrowhead Research Corporation, through its subsidiaries, engages in the identification, development, and commercialization of nanotechnology-related products and applications in the in the areas of life sciences, electronics, and energy in the United States. The company has developed Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers. Its lead anti-cancer drug candidate IT-101 is a combination of Cyclosert and the potent anti-cancer drug, camptothecin, is under Phase I clinical trials. Arrowhead Research also focuses on the design, development, and commercialization of novel RNA interference (RNAi) therapeutics to treat diseases and other medical conditions by combining RNAi therapeutics with patented and proprietary delivery technologies. Its CALAA-01 product is a formulation of proprietary delivery technology with a siRNA duplex targeting the M2 subunit of ribonucleotide reductase. In addition, the company engages in the manufacture and application of carbon nanotubes-based products for the electronics industry. Further, it focuses on the development of protective products based on the anti-oxidant properties of buckministerfullerenes. The company was founded in 2003 and is headquartered in Pasadena, California. More Info: Quote | Chart | Profile | Reports | Research | Msgs | Insider | Financials